【摘要】：目的:觀察康艾注射液對乳腺癌患者化療后生活質(zhì)量的影響。方法:選取2015年12月01日至2016年12月01日期間于中國人民解放軍武漢總醫(yī)院腫瘤科就診的60例女性乳腺癌根治術后患者作為研究對象。所有患者均擬行首次化療,其ECOG評分在0-1分之間,入組前常規(guī)檢查血常規(guī)、肝腎功能、心功能等大致正常,無明顯化療禁忌癥。60例乳腺癌術后患者隨機分成對照組(30例)和治療組(30例),兩組患者的臨床分期、分子分型、年齡均無明顯統(tǒng)計學差異(P0.05)。對照組采用吡喃阿霉素聯(lián)合環(huán)磷酰胺方案化療。治療組在化療前3天開始使用康艾注射液(60ml,靜滴,1/日),連續(xù)治療14天。兩組患者均常規(guī)使用類似的止吐、護胃、護肝等對癥治療。于化療后第10天分別檢查兩組患者血常規(guī)、肝腎功能、心功能,并用歐洲癌癥研究及治療組織生活質(zhì)量核心量表測定化療前后的生活質(zhì)量評分。結果:(1)對照組治療前與治療后對比數(shù)據(jù)可見:患者的情緒功能在治療后較治療前顯著降低(77.56±19.16 VS 70.12±16.20,P值0.023)�；颊咧委熀蟮钠＞�、失眠、食欲減退、惡心和嘔吐四項癥狀評分較治療前顯著升高(30.16±17.14 VS 41.56±19.12,P值0.019;16.14±22.45 VS 25.34±23.12,P值0.017;20.56±10.17VS 33.78±14.25,P值0.012;11.12±18.36 VS 27.78±20.16,P0.000)。(2)治療組治療前與治療后對比數(shù)據(jù)可見:患者治療后軀體功能、總體健康情況評分較治療前升高(62.13±22.56 VS 57.12±21.36,P值0.035;61.41±23.56 VS 51.12±24.36,P值0.022),疲倦評分較治療前下降(26.23±16.25 VS 32.23±15.54,P值0.028),食欲減退、惡心和嘔吐的評分較治療前明顯升高(27.21±13.26 VS 20.14±12.10,P值0.025;18.65±21.34 VS 10.56±19.78,P值0.031)。(3)兩組治療后比較:治療組的總體健康情況、軀體功能評分較對照組升高(61.41±23.56 VS 57.38±26.56,P值0.041;62.13±22.56 VS 55.86±23.42,P值0.038),疲倦、食欲減退及惡心和嘔吐的評分較對照組降低(26.23±16.25 VS41.56±19.12,P值0.013;27.21±13.26 VS 33.78±14.25,P值0.008;18.65±21.34 VS 27.78±20.16,P值0.011)。(4)兩組患者治療期間出現(xiàn)II度或以上白細胞減少發(fā)生率分別為43.3%(11例)和13.3%(4例),差異具有統(tǒng)計學意義(P值0.037)。I度及以上肝功能損害發(fā)生率分別為40.0%(12例)和16.7%(5例),差異具有統(tǒng)計學意義(P值0.045)。Ⅱ度或以上血紅蛋白減少、II度或以上血小板減少以及I度以上腎功能損害的發(fā)生率,兩組間對比無顯著的統(tǒng)計學差異(P0.05)。兩組患者均未出現(xiàn)心臟毒性。結論:在吡喃阿霉素聯(lián)合環(huán)磷酰胺化療基礎上加用康艾注射液能夠提高乳腺癌患者的軀體功能、總體健康狀況領域,改善化療引起的疲倦、食欲減退、惡心和嘔吐,雖然化療后仍會出現(xiàn)或加重惡心、嘔吐及食欲減退的癥狀,但程度明顯輕于單純化療,同時可減少II度及以上白細胞減少、I度及以上肝功能損害的發(fā)生率,提高了患者的生活質(zhì)量。
[Abstract]:Objective: to observe the effect of Kangai injection on quality of life of breast cancer patients after chemotherapy. Methods: 60 female breast cancer patients who were admitted to the Department of Oncology, Wuhan General Hospital of the Chinese people's Liberation Army from December 01, 2015 to December 1, 2016, were selected as the study objects. All patients were scheduled for the first time chemotherapy, and their ECOG scores ranged from 0 to 1. Routine examination of blood routine, liver and kidney function and cardiac function were normal before entering the group. No obvious chemotherapy contraindication. 60 cases of breast cancer patients were randomly divided into control group (30 cases) and treatment group (30 cases), the two groups of patients' clinical stage, molecular classification, age were not significantly different (P0.05). The control group was treated with adriamycin combined with cyclophosphamide regimen. The treatment group received Kangai injection 3 days before chemotherapy (60 ml, intravenous drip 1 / day) for 14 days. Patients in both groups were routinely treated with similar antiemesis, stomach care, liver protection and other symptomatic treatments. On the 10th day after chemotherapy, the blood routine examination, liver and kidney function, cardiac function were examined, and the quality of life scores before and after chemotherapy were measured with the European Cancer Research and treatment Organization quality of Life scale. Results: (1) compared with the control group before and after treatment, the emotional function of the patients decreased significantly after treatment (77.56 鹵19.16 vs 70.12 鹵16.20 P 0.023). The scores of fatigue, insomnia, anorexia, nausea and vomiting after treatment were significantly higher than those before treatment (30.16 鹵17.14 vs 41.56 鹵19.12 P 0.019 鹵22.45 vs 25.34 鹵23.12) P 0.017 20. 56 鹵10.17 vs 33.78 鹵14.25 P 0.012 11.12 鹵18.36 vs 27.78 鹵20.16 P0.000). (2 before and after treatment. The overall health score was higher than that before treatment (62.13 鹵22.56 vs 57.12 鹵21.36 P = 0.035 51.41 鹵23.56 vs 51.12 鹵24.36 P = 0.022), tiredness score decreased (26.23 鹵16.25 vs 32.23 鹵15.54 P = 0.028), appetite decreased. The scores of nausea and vomiting were significantly higher than those before treatment (27.21 鹵13.26 vs 20.14 鹵12.10 P = 0.025 鹵18.65 鹵21.34 vs 10.56 鹵19.78 P = 0.031). (3). After treatment, the overall health status and somatic function score of the treatment group were significantly higher than those of the control group (61.41 鹵23.56 vs 57.38 鹵26.56 P = 0.041 鹵62.13 鹵22.56 vs 55.86 鹵23.42 P 0.038). The scores of appetite loss and nausea and vomiting were lower than those of the control group (26.23 鹵16.25 vs 41.56 鹵19.12 P 0.013 鹵27.21 鹵13.26 vs 33.78 鹵14.25 P 0.008 18.65 鹵21.34 vs 27.78 鹵20.16 P 0.011). (4). The incidence of leukopenia II or above during treatment was 43.3% (11 cases) and 13.3% (4 cases), respectively. The incidences of degree I and above liver function damage were 40.0% (12 cases) and 16.7% (5 cases), respectively (P = 0.045). There was no significant statistical difference between the two groups (P0.05). There was no cardiac toxicity in both groups. Conclusion: adriamycin combined with cyclophosphamide can improve the body function, overall health status, fatigue, anorexia, nausea and vomiting in patients with breast cancer. Although the symptoms of nausea, vomiting and anorexia are still present or aggravated after chemotherapy, they are significantly less severe than those of chemotherapy alone, and can also reduce the incidence of degree II and above leukopenia I and liver dysfunction. The quality of life of the patients was improved.
【學位授予單位】：湖北中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R737.9

【參考文獻】

相關期刊論文 前10條

1 肖敏;劉瑛;田武生;龔璐;;康艾注射液聯(lián)合化療對中晚期結直腸癌免疫功能及中醫(yī)癥候的影響[J];當代醫(yī)學;2017年07期

2 王蘭榮;王海存;曹e，

本文編號：2128834